AFRJMS African Research Journal of Medical Sciences 3006-7421 Bioscience Press afrjms-3-1-001 10.62587/AFRJMS.1.1.2024.29-32 Short Communication Amentoflavone: Exploring potential therapeutic applications for diabetes mellitus FerrariIvan Vito 1 * Di MarioMauro 2 1Institute of Clinical Physiology, National Research Council, Via Aurelia Sud, 54100 Massa, Italy. E-mail: ivanvitoferrari@gmail.com 2Department Chemical Science and Technologies, Tor Vergata, Rome, Italy. E-mail: dimario@uniroma2.it *Corresponding author: Ivan Vito Ferrari, Institute of Clinical Physiology, National Research Council, Via Aurelia Sud, 54100 Massa, Italy. E-mail: ivanvitoferrari@gmail.com 01 2024 1 1 29 32 Abstract

Diabetes mellitus is acknowledged as a significant contributor to severe complications. The present work has explorated the potential role amentoflavone as an aldose reductase inhibitor through Docking Simulations. From these results this compound has shown excellent results with this enzyme with a high binding energy of -11 kcal/ mol. If amentoflavone,a natural biflavonoid, proves effective in inhibiting aldose reductase, it could hold therapeutic promise for managing diabetic complications. However, it is crucial to emphasize that while computational studies offer valuable insights, experimental validation is essential to confirm the actual inhibitory effects and to establish the safety and efficacy of amentoflavone for this purpose. Further research and clinical studies are warranted to fully understand and harness the potential therapeutic benefits of amentoflavone in the context of diabetes.

 Keywords Aldose reductase Diabetes mellitus Amentoflavone Docking analysis References American Diabetes Association. (2004). Gestational diabetes mellitus. Diabetes Care, 27: S88. BuchananT.A.XiangA. H. (2005). Gestational diabetes mellitus. The Journal of Clinical Investigation, 115(3): 485–491. ChenL.FangB.QiaoL.ZhengY. (2022). Discovery of anticancer activity of amentoflavone on esophageal squamous cell carcinoma: Bioinformatics, structure-based virtual screening, and biological evaluation. Microbiol Biotechnol, 32(6): 718–729. DunlopM. (2000). Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney international, 58(77): S3–S12. GargS. S.GuptaJ. (2022). Polyol pathway and redox balance in diabetes. Pharmacological Research, 182: 106326. KadorP.F.Robison JrW.G.KinoshitaJ. H. (1985). The pharmacology of aldose reductase inhibitors. Annual Review of Pharmacology and Toxicology, 25(1): 691–714. MengX.Y.ZhangH. X.MezeiM.CuiM. (2011). Molecular docking: a powerful approach for structurebased drug discovery. Current Computer-aided Drug Design, 7(2): 146–157. OdharH.A.RayshanA.M.AhjelS.W.HashimA.A.AlbeerA.A.M.A. (2019). Molecular docking enabled updated screening of the matrix protein VP40 from Ebola virus with millions of compounds in the MCULE database for potential inhibitors. Bioinformation, 15(9): 627. RamirezM.A.BorjaN.L. (2008). Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 28(5): 646–655. XiongX.TangN.LaiX.ZhangJ.WenW.LiX.LiuZ. (2021). Insights into amentoflavone: a natural multifunctional biflavonoid. Frontiers in Pharmacology, 12: 768708. YanL.J. (2018). Redox imbalance stress in diabetes mellitus: Role of the polyol pathway. Animal Models and Experimental Medicine, 1(1): 7–13.